$BHC News
Last published 5d ago
- 5d agoBHCBausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026PR NewswireBausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research...
- 2w agoBHCBausch Health Companies Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoBHCBausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027PR NewswireLAVAL, QC, Oct. 28, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its subsidiary, Bausch Health Americas, Inc., will issue an irrevocable notice of redemption dated as of October
- 2w agoBHCBausch Health Announces US$50 Million Share Repurchase ProgramPR NewswireLAVAL, QC, Oct. 28, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase its common
- 2w agoBHCBAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCEPR NewswireThird Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic1 basis over the prior year periodGAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of
- 1mo agoBHCSix-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical PathwayPR NewswireLAVAL, QC, Oct. 12, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study
- 1mo agoBLCOTSX:BLCOBHCTSX:BHCBausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 GuidanceBusiness WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas
- 1mo agoBHCBausch Health to Announce Third Quarter 2026 Results on October 28, 2026PR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2026 financial results after market close on Wednesday, October 28, 2026. ...
- 2mo agoBHCBausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA MarketsPR NewswireBausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and YUN, a Belgian innovator in pioneering...
- 2mo agoBHCBausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA MarketsPR NewswireBausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and YUN, a Belgian innovator in pioneering...
- 2mo agoBHCBausch Health Announces Availability of Solta Medical's Fraxel FTX® in AustraliaPR NewswireBausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, today...
- 2mo agoBHCBausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship WinnersPR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business, Ortho Dermatologics,...
- 2mo agoCNXULLYNVOABBV+1A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.GlobeNewswireIssued on behalf of Conexeu Sciences Inc. NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - For as long as aesthetic medicine has existed, its central promise has been to replace what time
- 2mo agoBHCBausch Health Announces 2026 Gastrointestinal Health Scholars Program WinnersPR NewswireFor the Seventh Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 ScholarshipLAVAL, QC, Aug. 17, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its
- 3mo agoBHCBLCOBausch Health CEO Thomas J. Appio Joins Bausch + Lomb BoardPR NewswireBausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been...
- 3mo agoBHCBAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCEPR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2026...
- 4mo agoBHCApproval of Onexton, Nda #050819 (Manufacturing (CMC))FDA Approved DrugsApproval Date: 07/11/2026; Drug Name: Onexton, Nda #050819; Active Ingredients: BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE; Company: Bausch; Submission Status: Approval; Submission Classification: Manufacturing (CMC); Application Number: 050819
- 4mo agoBHCApproval of Acanya, Nda #050819 (Manufacturing (CMC))FDA Approved DrugsApproval Date: 07/11/2026; Drug Name: Acanya, Nda #050819; Active Ingredients: BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE; Company: Bausch; Submission Status: Approval; Submission Classification: Manufacturing (CMC); Application Number: 050819
- 4mo agoBHCBausch Health to Announce Second Quarter 2026 Results on July 29, 2026PR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2026 financial results after market close on Wednesday, July 29, 2026....
- 4mo agoBHCMichael Goettler Resigns from Bausch Health's Board of DirectorsPR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Michael Goettler has resigned from its Board of Directors, effective June 30,...
- 5mo agoBHCBausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in ChinaPR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical...
- 5mo agoBHCBausch Health Announces 2026 Annual Meeting of Shareholder ResultsPR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of...
- 6mo agoBHCBausch Health to Participate in RBC Capital Markets 2026 Global Healthcare ConferencePR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Thomas J. Appio, Chief Executive Officer, and Jean-Jacques Charhon, Executive...
- 6mo agoBHCBausch Health to Participate in Barclays 30th Annual Leveraged Finance ConferencePR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate in a fireside chat at the...
- 6mo agoBHCBAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTSPR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2026 financial ...
- 7mo agoBHCBausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online OrderingPR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced Biafine® Skin Recovery Emulsion...
- 7mo agoBHCBausch Health to Announce First Quarter 2026 Results on April 29, 2026PR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026....
- 7mo agoBHCBausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship ProgramPR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the 2026 ASPIRE HIGHER...
- 8mo agoBHCBausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in CanadaPR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical...
- 8mo agoBHCBausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) MicrospheresPR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its dental products business, OraPharma, today announced the 25th anniversary milestone of...
- 8mo agoBHCBAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTSPR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth quarter and full-year 2025 ...
- 8mo agoBHCBausch Health to Participate in the J.P. Morgan Global Leveraged Finance ConferencePR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Executive Vice President and CFO Jean-Jacques (JJ) Charhon, along with other...
- 9mo agoBHCBausch Health Announces 2026 Gastrointestinal Health Scholars ProgramPR NewswireBausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the...
- 9mo agoBHCBausch Health Provides Update on RED-C Phase 3 Clinical TrialsPR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the results of the global Phase 3 RED-C clinical program evaluating...
- 9mo agoBHCBausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026PR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2025 financial results after market close on Wednesday,...
- 10mo agoBHCBausch Health to Participate in the 44th Annual J.P. Morgan Healthcare ConferencePR NewswireBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Thomas J. Appio, Chief Executive Officer, will participate at the 44th Annual...
- 10mo agoBHCBausch Health Announces Final Results and Expiration of Exchange OffersACCESS NewswireLAVAL, QC / ACCESS Newswire / December 23, 2025 / Bausch Health Companies Inc. and its subsidiary 1261229 B.C. Ltd. today
- 11mo agoBHCBausch Health Announces Early Exchange Offer Results for Exchange OffersACCESS NewswireLAVAL, QC / ACCESS Newswire / December 8, 2025 / Bausch Health Companies Inc. announced today the results to date of its previously announced offers to exchange the Company's
- 11mo agoBHCBausch Health's Aesthetics Business, Solta Medical, Acquires Longtime Distribution Partner, the Shibo Group, to Strengthen Presence in ChinaACCESS NewswireTransaction boosts Solta Medical's position to meet rising demand in China's growing aesthetics market LAVAL, QC / ACCESS Newswire / December 1, 2025 / Bausch Health Companies Inc. , a global,
- 11mo agoBHCBausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured NotesACCESS NewswireLAVAL, QC / ACCESS Newswire / November 24, 2025 / Bausch Health Companies Inc. today announced the commencement of offers to exchange the
- 11mo agoBHCBausch Health to Participate in the 8th Annual Evercore Healthcare ConferenceACCESS NewswireLAVAL, QC / ACCESS Newswire / November 18, 2025 / Bausch Health Companies Inc. , today announced that Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a
- 1y agoBHCBausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal DiseaseACCESS NewswireExpansion improves access to treatment options within periodontal care and helps strengthen partnerships with dental professionals within these populations. LAVAL, QC / ACCESS Newswire / November 5, 2025 / Bausch Health
- 1y agoBHCApproval of Wellbutrin Xl, Nda #021515 (Labeling)FDA Approved DrugsApproval Date: 11/05/2025; Drug Name: Wellbutrin Xl, Nda #021515; Active Ingredients: BUPROPION HYDROCHLORIDE; Company: Bausch; Submission Status: Approval; Submission Classification: Labeling; Application Number: 021515
- 1y agoBHCApproval of Aplenzin, Nda #022108 (Labeling)FDA Approved DrugsApproval Date: 11/05/2025; Drug Name: Aplenzin, Nda #022108; Active Ingredients: BUPROPION HYDROBROMIDE; Company: Bausch; Submission Status: Approval; Submission Classification: Labeling; Application Number: 022108
- 1y agoBHCBausch Health Announces Third Quarter 2025 ResultsACCESS NewswireThird Quarter Consolidated Revenues of $2.68 billion, up 7% on a Reported basis and 5% on an Organic 1 basis over the prior year periodGAAP Net Income Attributable to Bausch Health of $179 million and GAAP Net
- 1y agoBHCBausch Health Announces Results of Special Meeting of ShareholdersACCESS NewswireLAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. today announced the results of the special meeting of shareholders held on October 7, 2025 (the
- 1y agoBHCBausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TVACCESS NewswireThe Balancing Act airing on Lifetime will showcase how innovative treatments Thermage® FLX, Clear + Brilliant®, and Fraxel FTX™ offer energy-based treatment options that help maintain a youthful
- 1y agoBHCBausch Health to Announce Third Quarter 2025 Results on October 29ACCESS NewswireLAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025. Bausch Health will
- 1y agoBHCBausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to DentistryACCESS NewswireDesigned for dental professionals, OraTalks connects leading voices with insights to spark meaningful dialogue.Nine-episode inaugural season hosted by industry thought leader Melissa K. Turner, BASDH, RDHEP, EFDA, CHO.
- 1y agoBHCBausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease PortfolioACCESS NewswireThe transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAVAL, QC, AND